| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,890 |
2,581 |
$147K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,528 |
3,969 |
$117K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,553 |
905 |
$61K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,556 |
1,096 |
$42K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
214 |
207 |
$32K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
312 |
291 |
$18K |
| 80345 |
|
633 |
352 |
$15K |
| 80355 |
|
1,095 |
1,026 |
$13K |
| 80366 |
|
1,095 |
1,026 |
$13K |
| 80346 |
|
376 |
352 |
$12K |
| 80361 |
|
636 |
352 |
$11K |
| 80371 |
|
1,096 |
1,027 |
$11K |
| 80349 |
|
929 |
846 |
$11K |
| 80358 |
|
375 |
352 |
$10K |
| 80352 |
|
863 |
799 |
$10K |
| 80053 |
Comprehensive metabolic panel |
1,135 |
863 |
$10K |
| 80348 |
|
375 |
352 |
$10K |
| 80321 |
|
325 |
307 |
$9K |
| 80324 |
|
577 |
349 |
$8K |
| 80306 |
|
358 |
181 |
$8K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
561 |
390 |
$7K |
| 82542 |
|
1,266 |
1,166 |
$7K |
| 80362 |
|
1,112 |
1,044 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
97 |
92 |
$7K |
| 80369 |
|
374 |
351 |
$5K |
| 80354 |
|
375 |
352 |
$5K |
| 80356 |
|
375 |
352 |
$5K |
| 80353 |
|
374 |
351 |
$5K |
| 80372 |
|
356 |
333 |
$5K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
92 |
89 |
$4K |
| 80365 |
|
221 |
212 |
$4K |
| 0240U |
|
19 |
19 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
92 |
89 |
$3K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
851 |
629 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
129 |
111 |
$3K |
| 83992 |
|
78 |
78 |
$2K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
40 |
25 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
67 |
63 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
23 |
13 |
$856.79 |
| 81001 |
|
204 |
160 |
$773.02 |
| 84443 |
Thyroid stimulating hormone (TSH) |
60 |
52 |
$671.98 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
54 |
48 |
$646.70 |
| 71046 |
Radiologic examination, chest; 2 views |
51 |
35 |
$336.55 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
51 |
43 |
$325.24 |
| J3490 |
Unclassified drugs |
75 |
54 |
$223.56 |
| 80373 |
|
12 |
12 |
$197.50 |
| 99070 |
|
169 |
149 |
$155.73 |
| 87184 |
|
30 |
26 |
$153.48 |
| 87077 |
|
30 |
26 |
$152.94 |
| 87081 |
|
13 |
13 |
$121.74 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
34 |
25 |
$114.77 |
| 85610 |
|
74 |
54 |
$113.75 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
78 |
41 |
$97.18 |
| 86140 |
|
16 |
15 |
$81.24 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
39 |
38 |
$73.46 |
| 85652 |
|
16 |
15 |
$63.37 |
| 80305 |
|
788 |
522 |
$42.33 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
21 |
13 |
$38.79 |
| 36415 |
Collection of venous blood by venipuncture |
1,407 |
1,054 |
$29.65 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
573 |
509 |
$10.40 |
| A4335 |
Incontinence supply; miscellaneous |
28 |
28 |
$3.89 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
286 |
275 |
$0.00 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
105 |
104 |
$0.00 |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
14 |
12 |
$0.00 |